Journal Information

Statistics

Follow this link to access the full text of the article

Correspondence
No evidence for cardiotoxicity of miltefosine – Reply
Daniel Holanda Barrosoa,
Corresponding author
Danielhbarroso@unb.br

Corresponding author.
, Ciro Martins Gomesa,b,c, Antônia Marilene da Silvad, Raimunda Nonata Ribeiro Sampaioa
a Faculty of Medicine, Universidade de Brasília, Brasília, DF, Brazil
b Dermatomycology Laboratory, Faculty of Medicine, Universidade de Brasília, Brasília, DF, Brazil
c Tropical Medicine Center, Universidade de Brasília, Brasília, DF, Brazil
d Hospital Universitário de Brasília, Universidade de Brasília, Brasília, DF, Brazil
Read
2518
Times
was read the article
1118
Total PDF
1400
Total HTML
Share statistics
Article information
ISSN: 03650596
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2024 April 52 46 98
2024 March 75 48 123
2024 February 86 78 164
2024 January 60 55 115
2023 December 57 50 107
2023 November 67 86 153
2023 October 52 69 121
2023 September 65 74 139
2023 August 45 30 75
2023 July 51 29 80
2023 June 61 39 100
2023 May 41 24 65
2023 April 37 12 49
2023 March 55 41 96
2023 February 35 27 62
2023 January 44 33 77
2022 December 58 25 83
2022 November 65 56 121
2022 October 122 52 174
2022 September 50 64 114
2022 August 56 47 103
2022 July 129 88 217
2022 June 37 45 82
Show all

Follow this link to access the full text of the article

Idiomas
Anais Brasileiros de Dermatologia
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.